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A new spectrophotometric method based on the formation of an ion-pair using bromothymol blue as
ion-pair complexing reagent was developed for the determination of mexiletine hydrochloride in capsules.
The ion-pair formed was highly coloured and easily extracted with dichloromethane. The calibration
curve was linear over the concentration range 1.08–10.8 µg.ml−1 at λmax = 408 nm (r = 0.9999). The
results obtained from the developed method were compared statistically with those obtained by the
British Pharmacopeia method.
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Introduction
Mexiletine hydrochloride (MH), [1-(2,6-(dimethylphenoxy)-2-aminopropane hyrochloride], is an antiarrhthymic
drug used for treatment of ventricular arrhythmias1−3 . Although a variety of UV-spectrophotometry4 ,
fluorimetry5 , gas6,7 and high performance liquid chromatography8,9 techniques for assaying mexiletine in
both capsules and biological materials have been described, only a derivative spectrophotometric method10
has been reported. More recently, a spectrophotometric method based on the formation of ion-pair complexes
with methyl orange was reported11 . Since there are serious side effects of MH, namely tachycardia, arterial
fibrillation, hypotension and need to follow the patient during treatment, rapid and sensitive methods for
the determination of MH are still required. In this study, our aim was to develop a new more sensitive spectrophotometric determination method for the analysis of mexiletine hydrochloride and its capsules based on
the formation of an ion-pair with bromothymol blue (BTB) as an ion-pair complexing reagent.

Experimental
Materials and methods
Apparatus
A Shimadzu UV-160 A UV-visible spectrophotometer with 1 cm path length glass and quartz cells and
WTW pH 526 pH meter with a combined glass electrode were used.
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Chemicals
Mexiletine hydrochloride and capsules of it (Mexitil r ) were kindly supplied by Eczacıbaşı Pharmaceuticals (İstanbul, Turkey). The other chemicals and solvents used were analytical reagent grade. Bidistilled
water was used throughout the work.

Stock solution of MH
About 10.8 mg of MH was dissolved in 50 ml of water (1 x 10−3 M).

Reagent solution
About 187.2 mg of BTB was dissolved in 50 ml of 5% alcohol (5.99 x 10−3 M).

Procedures
Preparation of Calibration Graph
Suitable aliquots of the stock solution of MH (0.25–2.5 ml) were transferred to stoppered glass tubes and
2.5 ml of the stock solution of BTB (5.99 x 10−3 M) was added to each of them. Then the mixture was
extracted with 5 ml dichloromethane by vortex mixer for 2 min; 1 ml of the organic phases was put into a
calibrated flask, and diluted to 10 ml with dichloromethane. Absorbance values were measured at 408 nm
against a blank solution which was prepared in a similar way. The calibration graph of MH was plotted and
the regression equation was calculated.

Assay Procedure for Capsules
Capsule powder equivalent to about 200 mg of MH was accurately weighed and transferred into a 250 ml
calibrated flask. Then 100 ml of water was added, and the mixture was shaken mechanically for 1 h and
diluted to volume with water, and mixed and filtered. Then 0.25 ml of filtrate was taken from this solution,
and the same procedure was applied as described above for the calibration graph. The amount of MH in
capsules was calculated from the regression equation of the calibration graph.

Results and Discussion
Optimum ion-pair formation conditions with respect to solvent, pH, time and amount of the reagent were
investigated. The ion-pair formed was highly coloured and easily extracted with dichloromethane. The
absorption spectrum in CH2 CI2 showed a maximum at 408 nm. Buffer solutions (phosphate buffer pH =
5–8) were tried, but the ion-pair showed the highest absorbance in the nonbuffer solution. The final solution
was stable for 18 h at room temperature in darkness. The stoichiometric ratio of MH / BTB was found to be
1:1 by Job’s curve. The optimum molar ratio of reagent to MH was found to be 6 by the molar ratio method
(Figure 1). Under these conditions, a linear correlation was observed between absorbance and concentration
of MH over the range 1.08–10.8 µg.ml−1 (Figure 2). The regression equation was A = 0.0906 c + 0.0137
with a the correlation coefficient r = 0.9999.
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Figure 1. Effect of mole ratio of BTB to mexiletine hydrochloride.
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Figure 2. Calibration curve.

The proposed method was applied to commercially avaliable capsules. The results were compared
with those obtained by the official method4 . Statistical comparisons in terms of t- and F-tests for these
methods given in the Table. There are no significant differences between the proposed method and the
official method with respect to the mean values and standard deviations at a 95% confidence level.
Table. Comparison of the results obtained by spectrophotometric and UV- spectrophotometric methods for the
assay of MH in capsules.

Sttatistical values

Proposed method

Mean (mg)
Recovery ∓ standard
deviation, [%]
Confidence limits
t-test∗
F-test∗
*n=6

p = 0.05

200.13
100.06 ∓ 1.02

UV-spectrophotometric method
(BP 1993)
200.19
100.09 ∓ 0.76

200.13 ∓ 0.93

t = 2.23

200.19 ∓ 0.69
0.12
1.79

F = 5.05 (each capsule contains 200 mg of MH)

The proposed method was also compared with a reported method11 with respect of the linear ranges
and statistically values. The linear range in the reported method was 1.1-7.6 µg.ml−1. The proposed
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method was more accurate and precise in terms of t- and F-tests. Moreover, maximum absorbance occurred
in phthalate buffer in the reported work, whereas the highest absorbance was obtained in the nonbuffer
solution in this work. The stability of the colour of ion-pair formation has also not been investigated11 .
The results show that this method is simple, accurate and precise and it can be recommended for the
routine pharmaceutical analysis of mexiletine hydrochloride.
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